Trial Profile
A Phase 2 Randomized, Open-Label Trial of PA-824-Containing Regimens Versus Standard Treatment for Drug-Sensitive Sputum Smear-Positive Pulmonary Tuberculosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jul 2023
Price :
$35
*
At a glance
- Drugs Pretomanid (Primary) ; Ethambutol; Isoniazid; Pyrazinamide; Rifabutin; Rifampicin
- Indications Pulmonary tuberculosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms APT
- 01 Dec 2022 Primary endpoint has been met, (Time to sputum culture conversion on liquid medium) as per Results published in the American Journal of Respiratory and Critical Care Medicine
- 01 Dec 2022 Results published in the American Journal of Respiratory and Critical Care Medicine
- 18 May 2022 Status changed from recruiting to completed.